FACTORS ASSOCIATED WITH IMPROVED CLINICAL CONTROL IN A DIFFICULT-TO-TREAT PAEDIATRIC ASTHMA COHORT THROUGH THE COVID-19 PANDEMIC LOCKDOWN PERIOD

It can also cause a clinically apparent, idiosyncratic liver injury. Onset is usually within 2 to 12 weeks of starting therapy and typically causes a cholestatic or mixed pattern of enzyme elevations, without evidence of hepatic necrosis on liver biopsy.2 Most patients recover on drug discontinuation. There are, however, occasional reports of severe and fatal cases. The proposed mechanism of carbimazole‐induced cholestasis is not fully understood.1